Neurophet announced on Thursday that it has entered into a supply agreement with Elevate Clinic in the U.S. for its Neurophet Aqua and Neurophet Aqua AD Plus products.
Elevate Clinic, based in Texas, is a specialized medical institution focusing on neurological disorders. The clinic operates six facilities across major Texan cities and is renowned for its comprehensive care system for patients with traumatic brain injuries and other neurological conditions.
Traumatic brain injury is a major health concern in the U.S., placing a significant burden on both patients and healthcare providers. Accurate detection of brain volume changes and microbleeds resulting from brain injuries is crucial. Neurophet Aqua’s brain volume measurement and atrophy analysis capabilities, along with Neurophet Aqua AD Plus’s microbleed detection features, can be valuable tools in analyzing brain imaging for traumatic brain injury patients.
Neurophet Aqua is an advanced neuroimaging analysis software that rapidly performs quantitative analysis of patients’ brain magnetic resonance imaging (MRIs). It examines brain atrophy and white matter degeneration, providing customized analysis reports by quantifying changes observed in neurodegenerative diseases such as Alzheimer’s and vascular dementia.
Neurophet Aqua AD Plus is a comprehensive analysis solution offering brain imaging analysis functions essential for prescribing Alzheimer’s medications. Using artificial intelligence (AI) based brain MRI analysis, it can automatically detect and analyze the location and number of low-intensity lesions linked to superficial siderosis and high-intensity lesions associated with brain edema.
This supply agreement marks a significant milestone, establishing a clinical foundation for AI-powered brain imaging analysis solutions in specialized neurological institutions in the U.S. Neurophet aims to expand its clinical applications across regional hospitals in the country, using this as a springboard to accelerate its growth in the American market.
Bin Jun-gil, co-Chief Executive Officer (CEO) of Neurophet, stated that by supplying our key products to Elevate Clinic in the U.S., it’s expanding the global reach. He added that it plans to intensify the efforts to increase product supply, focusing on major medical institutions across North America.
Neurophet, founded in 2016, is a specialized company developing AI-powered brain disease solutions that span the entire treatment cycle. Its flagship products include the neurodegeneration imaging analysis software Neurophet Aqua and Neurophet Aqua AD, which monitors the prescription and treatment effects of dementia medications.
